Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis

Avacopan is a relatively novel drug with complement antagonizing properties, and it has demonstrated promising outcomes in treating antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. This review article seeks to investigate the current standard of care for ANCA vasculitis with the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical drug investigation 2023-08, Vol.43 (8), p.595-603
Hauptverfasser:	Nguyen, Ivan D., Sinnathamby, Evan S., Mason, Joseph, Urban, Bretton, Neuchat, Elisa E., Wenger, Danielle M., Ahmadzadeh, Shahab, Shekoohi, Sahar, Kaye, Alan D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood vessels Cardiovascular disease Clinical trials Diabetes Disease control Drug dosages FDA approval Immunosuppressive agents Inflammation Internal Medicine Kidneys Medicine Medicine & Public Health Neutrophils Osteoporosis Pharmacology/Toxicology Pharmacotherapy Remission (Medicine) Review Article Steroids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!